Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
8
×
deals
life sciences
national blog main
biotech
national top stories
boston
clinical trials
fda
new york blog main
new york top stories
san francisco blog main
san francisco top stories
alexion pharmaceuticals
boehringer ingelheim
eli lilly
gene therapy
johnson & johnson
new york
novartis
rna interference
san diego blog main
san diego top stories
sanofi
startups
acetylon pharmaceuticals
achromatopsia
alirocumab
alnylam pharmaceutials
alnylam pharmaceuticals
ambys medicines
amgen
amyotrophic lateral sclerosis (als)
arrowhead pharmaceuticals
atrial fibrillation
autoimmune disorders
beta-thalassemia
bill cassidy
biontech
What
deal
8
×
medicines
new
rna
acquire
billion
companies
drug
fda
gene
pharma
second
startup
therapy
time
abandoning
adding
age
ago
agreed
aiming
alternative
ambys
approval
atrial
autoimmune
baggage
bets
betting
big
bigger
biggest
bio
biopharma
biotech
boston
brings
business
cancer
candidate
Language
unset
Current search:
deal
×
" boston top stories "
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines